Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis

Our results demonstrate that ETI exerts rapid and sustained effects on systemic inflammation associated with lung function improvements in children, adolescents and adults with cystic fibrosis in a real-world, post-approval setting. However, our data also show that individual markers of systemic inflammation remain at levels above those of healthy controls, particularly in certain subgroups, suggesting persistence or resurgence of residual systemic inflammation.

Authors

Institutions

Publication Details

Journal
European Respiratory Journal
Published
2025-09-18
DOI
https://doi.org/10.1183/13993003.00150-2025
Citations
4
Primary Topic
Cystic Fibrosis Research Advances
Type
article
Field-Weighted Citation Impact
6.07
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis

Katharina Schütz, Folke Brinkmann, Stephanie A. Thee, Stephanie Hirtz et al.
4 citations
European Respiratory Journal
Cystic Fibrosis Research Advances
6.07
article

Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis

Katharina Schütz, Folke Brinkmann, Stephanie A. Thee, Stephanie Hirtz, Ruth Grychtol, Julia Kontsendorn, Tatjana Uselmann, Jobst Roehmel, Olaf Sommerburg, Anna‐Maria Dittrich, Burkhard Tümmler, Felix C. Ringshausen, Marcus Alexander Mall, Johannes Schwabe, Lutz Naehrlich, Bianca Schaub, Iris Kühbandner, Jan-Niklas Falke, Simon Y. Graeber, Claudia Kessemeier, Jaehi Chung, Zulfiya Syunyaeva, Markus Weckmann, Claudia Rückes-Nilges, Olga Halle, Silke van Koningsbruggen‐Rietschel, Gesine Hansen, Stefanie Widder, Mirjam Stahl, Mustafa Abdo, Julia Duerr, Sophia T. Pallenberg, Stefanie Weber, Sandra Barth, Rebecca Dalferth, Azadeh Bagheri-Pothoff
article en
4 citations

Abstract

Our results demonstrate that ETI exerts rapid and sustained effects on systemic inflammation associated with lung function improvements in children, adolescents and adults with cystic fibrosis in a real-world, post-approval setting. However, our data also show that individual markers of systemic inflammation remain at levels above those of healthy controls, particularly in certain subgroups, suggesting persistence or resurgence of residual systemic inflammation.

European Respiratory JournalVol. 66(6)
American Institute of Biological Sciences (US), Justus-Liebig-Universität Gießen (DE), Heidelberg University (DE), University Hospital Heidelberg (DE), Medizinische Hochschule Hannover (DE), Humboldt-Universität zu Berlin (DE), Equilibrium Research (GB), Research Center Borstel - Leibniz Lung Center (DE), German Center for Lung Research (DE), Center for Health and Gender Equity (US), Universities of Giessen and Marburg Lung Center (DE), Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), University Hospital Cologne (DE), Freie Universität Berlin (DE), Medical University of Vienna (AT), Charité - Universitätsmedizin Berlin (DE), Ludwig-Maximilians-Universität München (DE), Deutsche Forschungsgemeinschaft (DE), University of Lübeck (DE)
Openalex Percentile: Top 3%
Cystic Fibrosis Research Advances
6.07
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.